Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of Bulimia Nervosa in a Primary Care Setting
This study has been completed.
Study NCT00009178   Information provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First Received: January 23, 2001   Last Updated: June 23, 2005   History of Changes

January 23, 2001
June 23, 2005
March 1998
 
 
 
Complete list of historical versions of study NCT00009178 on ClinicalTrials.gov Archive Site
 
 
 
Treatment of Bulimia Nervosa in a Primary Care Setting
 

Bulimia Nervosa is a frequent problem for young women. It is widely assumed that this disorder cannot be treated effectively in a primary care setting. This assumption has never been tested empirically, and is probably incorrect.

In the last 15 years, effective treatment interventions for Bulimia Nervosa have been developed and validated in specialized treatment centers. The broad aim of this proposal is to examine whether these treatments, suitably adapted, can be usefully transferred to general health care settings. Specifically, the proposed study will determine the relative and combined effectiveness of the two leading treatments for Bulimia Nervosa in a primary care setting. The two major interventions are treatment with an antidepressant medication, fluoxetine, and with a form of cognitive behavioral therapy, guided self-help, designed for use in primary care.

 
 
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Bulimia Nervosa
  • Drug: Fluoxetine
  • Behavioral: Guided Self-Help
 
Waller D, Fairburn CG, McPherson A, Kay R, Lee A, Nowell T. Treating bulimia nervosa in primary care: a pilot study. Int J Eat Disord. 1996 Jan;19(1):99-103.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
December 2001
 

Inclusion Criteria:

  • DSM-IV criteria for bulimia nervosa with a modified frequency criterion of at least once a week

Exclusion Criteria:

  • Physical disorder requiring hospitalization or ongoing treatment likely to affect eating and/or weight
  • Significant suicidal ideation or behavior
  • Subjects judged unable to tolerate four-month treatments available in the study because of comorbid psychiatric conditions
  • Current drug or alcohol dependence
  • Current anorexia nervosa
  • Pregnancy or any physical condition or treatments known to influence eating and weight
  • Current psychiatric treatment or medication known to affect eating or weight
  • Previous course of fluoxetine at a dose of 60 mg. per day for at least four weeks
  • Allergy to fluoxetine
  • Previous course of cognitive behavioral therapy for Bulimia Nervosa at a qualified center
Female
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00009178
 
Walsh, R01DK53635-03
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 
Principal Investigator: B. T. Walsh, MD Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
May 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP